Several months ago, I wrote about a critical shift in cancer care: appendix cancer was finally recognized as a distinct disease, no longer treated as colon cancer.
That change addressed classification.
The latest consensus guidelines address something equally important. How these cancers are treated once they spread to the peritoneum.
A More Defined, but Still Complex Treatment Framework
Historically, peritoneal metastases were associated with limited treatment options and poor outcomes. Most patients were treated with palliative chemotherapy and supportive care, with median survival measured in months.
Over the past two decades, that model has changed significantly with the introduction of:
- Cytoreductive surgery
- Hyperthermic intraperitoneal chemotherapy
- Increasingly disease-specific research
As treatment options expanded, variability also increased. Patients with similar diagnoses often received very different recommendations depending on where they were treated.
These consensus guidelines represent an effort to reduce that variability by establishing a shared, evidence-informed framework for care.
How This Builds on the 2025 Chicago Consensus and NCCN Guidelines
The 2025 Chicago Consensus and NCCN guidelines introduced a structural shift in appendiceal cancer care:
- Grade-based treatment strategies
- A stronger role for systemic chemotherapy in high-grade disease
- Standardized surveillance protocols
- Emphasis on referral to specialized peritoneal malignancy centers
This moved the field away from treating appendix cancer as a subset of colorectal cancer and toward a disease-specific framework.
The current consensus work builds on that foundation and moves one step further toward treatment selection based on tumor biology.
Then vs Now: How Management Is Evolving
| Area | Pre-2025 | 2025 Guidelines | Current Direction |
|---|---|---|---|
| Classification | Treated as colon cancer | Recognized as distinct | Further refined by subtype |
| Treatment Approach | Uniform | Grade-based | Biology-driven |
| Surgery | Often first-line | Selective | Based on disease behavior |
| Chemotherapy | Colon-based regimens | Standard in high-grade | Re-evaluated by molecular profile |
| HIPEC | Broad use | More selective | Indication-specific |
| Surveillance | General GI model | Structured protocols | Moving toward molecular risk |
Why High Grade Is No Longer Enough
One of the limitations of current frameworks is that they still group multiple biologically distinct diseases under the label of high-grade appendiceal cancer.
In practice, this includes at least three different entities.
High-Grade Mucinous Adenocarcinoma (HGMA)
- Gland-forming, mucin-producing tumors
- Frequently driven by KRAS mutations
- Commonly spread within the peritoneum
Recent research, including our breakdown of KRAS and PIK3CA co-mutations, suggests that when these mutations occur together, they can significantly increase replication stress, genomic instability, and tumor aggressiveness.
This helps explain why tumors that appear similar under a microscope can behave very differently in practice.
High-Grade Signet Ring Cell Carcinoma (SRCC)
- Defined by intracellular mucin displacing the nucleus
- Represents a poorly differentiated and aggressive phenotype
- Associated with diffuse peritoneal spread and worse outcomes
Signet ring features are clinically meaningful. Even a small percentage can influence prognosis and treatment decisions.
Goblet Cell Adenocarcinoma (no called “GCA”)
Goblet cell adenocarcinoma remains one of the most complex appendiceal tumor types and is discussed in more detail here:
Goblet Cell: Why is it still being treated like Colon Cancer?
Key characteristics include:
- Mixed adenocarcinoma and neuroendocrine features
- Distinct molecular profile
- Strong tendency for peritoneal spread
- Typically microsatellite stable and low tumor mutational burden
Treatment is still commonly based on colorectal regimens such as FOLFOX or FOLFIRI because disease-specific trials are limited.
The Core Issue: One Framework, Multiple Diseases
The current guidelines represent progress, but still rely heavily on:
- Histologic grade
- Surgical resectability
- General disease patterns
They do not yet fully incorporate molecular co-mutation patterns, tumor microenvironment differences, or hybrid tumor biology.
As a result, distinct diseases are still being managed within a partially unified system.
“High-grade” remains an overly broad category. Even with these advances, HGMA, SRCC, and GCA are still often treated as though they are the same disease, despite clear biological differences. This is exactly why more research is needed. In rare cancers like appendix cancer, that research does not happen unless it is funded externally, as these diseases are not a “financial priority” within most healthcare systems. Rare Cancers are not money makers.
On a more positive note, the key shift in these guidelines IS the move away from uniform treatment strategies.
This reflects a transition toward precision oncology, where treatment decisions are increasingly driven by tumor biology – at least for some of the Appendix Cancer population.
Where the Field Is Heading
The trajectory is clear:
- From organ-based treatment to disease-specific treatment
- From grade-based decisions to biology-driven decisions
- From uniform protocols to molecular stratification
The current guidelines represent an intermediate step in a rapidly evolving field.
Final Perspective
The development of consensus guidelines signals that care for peritoneal surface malignancies is becoming more structured, collaborative, and evidence-based.
At the same time, meaningful differences in tumor biology continue to drive variation in outcomes and treatment response.
Future progress will depend on deeper molecular characterization, disease-specific clinical trials, and integration of targeted therapies.
Understanding tumor biology is increasingly central to understanding the treatment plan.
Appendix Cancer Types at a Glance
| Feature | HGMA | GCA | SRCC |
|---|---|---|---|
| What it is | Mucin-producing adenocarcinoma | Mixed adenocarcinoma and neuroendocrine tumor | Poorly differentiated aggressive cells |
| Behavior | Variable | Often aggressive and unpredictable | Highly aggressive |
| Common mutations | KRAS, sometimes PIK3CA | KRAS, TP53 and others | KRAS and others |
| Spread pattern | Peritoneal, mucinous | Peritoneal | Diffuse peritoneal spread |
| Treatment approach | CRS, HIPEC, chemo depending on case | Often treated like colon cancer due to lack of data | Treated as high-grade aggressive disease |
| Key challenge | Variable behavior | No standardized treatment | Poor prognosis |
Anals of Surgical Oncology: New Consensus Statements for Peritoneal Surface Malignancy – Edward Levine, MD Surgical Oncologist and Section Head of Surgical Oncology at Atrium Health Wake Forest Baptist – March 21,202
Leave a Reply